# Jacky Abitbol

> Jacky Abitbol is a Series B investor at Cathay Innovation backing Artificial Intelligence. See 32 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Cathay Innovation](https://shizune.co/investors/profile/cathay-innovation-fund)
- Location: Paris, France
- Total investments: 32
- Last investment: May 2026
- Lead investor: 56%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jacky-abitbol-875a632/
- X (Twitter): https://twitter.com/natmaxabit
- Facebook: https://www.facebook.com/jacky.abitbol

Jacky Abitbol is a Partner at Cathay Innovation, based in Paris. He benefits from over 17 years of advisory and operational experience in Telecommunications, Medias and Technology, with a particular expertise in venture capital and corporate development.Prior to joining Cathay Capital, Jacky was a Venture Partner with Iris Capital in Israël from2012 to 2015. In this role, he was responible for identifying investment opportunities for Iris Capital and monitoring local portfolio companies. In addition Jacky headed the Corporate Development activity for Orange startups program. Before, he was Vice President for Corporate Development at Orange Digital from 2012 to 2013 and Investment Director at Orange Capital (now Iris Capital) from 2011 to 2012.Previously, Jacky Abitbol was Business Development & Sales Director for the mobile division of SanDisk from 2006 to 2011 and worked as a Corporate and Business Development Director at GFI in Spain from 2003 to 2006.He started his career as part of the management team of Fantine Group (now Aviv Ventures).Jacky holds a MBA from Boston University and a degree in Business Administration from Madrid Business School.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $19M–$45M |
| Series B | $24M–$60M |
| Series C | $21M–$109M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 7 | 22% |
| FinTech | 4 | 13% |
| Health Care | 4 | 13% |
| Information Technology | 4 | 13% |
| Software | 3 | 9% |

58 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 31% |
| Series A | 6 | 19% |
| Series C | 4 | 13% |
| Funding Round | 3 | 9% |
| Seed | 2 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 10 | 31% |
| Spain | 5 | 16% |
| United States | 2 | 6% |
| Sweden | 1 | 3% |
| Belgium | 1 | 3% |

6 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Embat | Embat develops cloud-based treasury management software designed to help finance teams manage cash flow, banking operations, and financial forecasting in real time. The company provides a platform that connects bank accounts, enterprise resource planning systems, and payment systems to centralize visibility of cash positions across multipleentities and currencies. Its software supports automated reconciliation, payment execution, liquidity forecasting, and financial reporting through a unified interface. The platform also includes AI-driven features that assist with transaction matching, anomaly detection, and cash flow prediction to reduce manual finance operations. Embat works with mid-sized and large enterprises to streamline treasury workflows, improve liquidity management, and support financial decision-making. The company integrates with a wide network of financial institutions and enterprise systems to enable continuous financial data synchronization and operational control.The platform uses automation and AI features to reduce manual treasury tasks, including transaction matching, accounting entries, and financial reporting workflows. It integrates with a wide range of banking systems and corporate ERPs to synchronize financial data continuously. Embat also enables centralized payment management, allowing finance teams to initiate, approve, and track transactions across multiple banking relationships. Its tools support cash visibility, debt monitoring, and financial scenario planning for operational decision-making. | $35.3M | Series B | May 12, 2026 |  |
| Tucuvi | Tucuvi is a health technology company unlocking efficient and high-quality healthcare at scale with a CE-marked platform for Phone Consultation Automation. We develop safe and clinically validated Conversational AI for any care pathway, enabling clinical teams to augment their capacities, improve processes’ efficiency and efficacy, and achievebetter patient outcomes and satisfaction through continuous and personalized care. | $20M | Series A | Jan 08, 2026 |  |
| Nabla | Nabla develops AI-powered tools focused on healthcare, particularly in medical imaging and diagnostics. The company creates solutions that assist medical professionals in detecting and analyzing conditions through advanced machine learning algorithms. Nabla's technology aims to enhance diagnostic accuracy and streamline clinical workflows byintegrating with existing healthcare systems. The company collaborates with medical institutions to improve patient outcomes using AI-driven insights. Its offerings include software platforms designed for radiology and pathology applications. | $70M | Series C | Jun 17, 2025 |  |
| Abacum | Abacum is a SaaS that helps finance teams deliver business insights. Abacum is the first collaborative workflow and planning platform for SMB's finance teams to boost productivity and strategic impact. The company believes in empowering people with the best collaborative tools for them to multiply their strategic impact in the organization andbe more fulfilled. | $60M | Series B | Jun 11, 2025 |  |
| Bioptimus | Bioptimus is a developer of a universal AI foundation model that connects biology at all sizes, from molecules to cells, tissues, and entire organisms. The company's technology turns multiscale data into actionable representations, allowing clients to spark breakthrough discoveries and expedite biomedical innovation. | $41M | Series A | Jan 14, 2025 |  |
| AQEMIA | AQEMIA is a pharmatech company developing a drug discovery platform to discover new drugs for specific therapeutic targets. Its platform combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a growing pipeline of new drug candidates. The company utilizes advanced techniques, including generative AIand atomic scale physics, to design novel drugs tailored for specific therapeutic targets. | $38M | Series A | Dec 10, 2024 |  |
| Entalpic | Entalpic is an AI-driven discovery platform for sustainable industries aiming to optimize carbon-intensive sectors. | $9.4M | Seed | Sep 04, 2024 |  |
| Firstvet | FirstVet is a video consultation platform that connects veterinarians, directly on the user's smartphone, tablet, or computer.The app aims to care about a pet and offers help and advice. It helps users to determine when they need to seek care for a pet suffering from stomach problems. They provide consultation, medicinal prescriptions, andrelated services through both mobile applications and their website. Founded in 2016, the company is headquartered in Stockholm, Stockholms Lan, Sweden by David Prien and Joakim Widigs. | $21.5M | Series C | Jun 24, 2024 |  |
| Resilience | Resilience Care is building a software-based solution for cancer treatment providers and patients. By integrating a mobile application with a Remote Patient Monitoring platform, Resilience enhances care by personalizing, humanizing, and improving the care pathway. The mobile application aids individuals affected by cancer in managingtreatment-related side effects and promoting self-care. Simultaneously, the Remote Patient Monitoring platform, classified as a Class IIa medical device, allows healthcare professionals to better understand and improve patient care. | $25M | Venture - Series Unknown | May 21, 2024 |  |
| Flowdesk | Flowdesk is a regulated, full-service digital asset trading and technology firm that specializes in market making, OTC, and treasury management services. Company registered in France - no. 883604647Registered Digital Asset Service Provider with the AMF for digital assets custody, purchase/sale of digital assets for legal tender and tradingof digital assets for other digital assets number: E2021-019 | $50M | Series B | Jan 18, 2024 |  |

10 of 32 investments shown.

## Co-investors
- [Cathay Innovation](https://shizune.co/investors/profile/c-entrepreneurs) — VC Fund, 23 deals together
- [Seaya](https://shizune.co/investors/profile/seaya-ventures) — VC Fund, 12 deals together
- [Korelya Capital](https://shizune.co/investors/profile/korelya-capital) — VC Fund, 4 deals together
- [Encomenda VC](https://shizune.co/investors/profile/encomenda-vc-2) — VC Fund, 3 deals together
- [Eurazeo](https://shizune.co/investors/profile/eurazeo-com) — VC Fund, 3 deals together
- [Iberdrola](https://shizune.co/investors/profile/iberdrola) — VC Fund, 3 deals together

## About Cathay Innovation

VC Fund · San Francisco, United States

Cathay Innovation is a multistage venture capital firm affiliated with Cathay Capital, investing in founders building transformative businesses across Europe, North America, Asia, Latin America, and Africa. Its platform connects founders with investors and its ecosystem of leading Fortune 500 corporations to help startups scale and transformindustries with consumer-to-enterprise and AI solutions in commerce, fintech, digital health, and mobility/energy. Cathay Innovation now manages over €2.5B AUM with offices in Paris, Berlin, Madrid, San Francisco, Mexico City, Shanghai, and Singapore and has invested in over 150 startups, including Chime, Pinduoduo (NASDAQ: PDD), Glovo, Wallbox (NYSE: WBX), Owkin, Ledger, ZenBusiness, Alma, Descartes Underwriting, and more.

5 contacts available at Cathay Innovation.

| Name | Title | Profile |
| --- | --- | --- |
| Rajive Keshup | Partner | https://shizune.co/investors/profile/rajive-keshup |
| Costanza Carissimo | Director | https://shizune.co/investors/profile/costanza-carissimo |
| Denis Barrier | Co-founder and CEO | https://shizune.co/investors/profile/denis-barrier |
| Jacky Abitbol | Managing Partner | https://shizune.co/investors/profile/jacky-abitbol |
| John Li | Partner | https://shizune.co/investors/profile/john-li-1c00 |

## Similar investors

### Similar industry
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [All Angel Investors in Spain](https://shizune.co/investors/angel-investors-spain)
- [Automotive Investors in Spain](https://shizune.co/investors/automotive-investors-spain)
- [Automotive Angel Investors in Europe](https://shizune.co/investors/automotive-angel-investors-europe)
- [Automotive Angel Investors in Spain](https://shizune.co/investors/automotive-angel-investors-spain)
- [Transportation Angel Investors in Spain](https://shizune.co/investors/transportation-angel-investors-spain)

## FAQ

### What does Jacky Abitbol invest in?

Jacky Abitbol invests primarily in Artificial Intelligence, FinTech and Health Care startups, most often at Series B and Series A stage. Most of the 32 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Jacky Abitbol's check size?

Jacky Abitbol typically joins rounds of $19M–$45M at Series A, $24M–$60M at Series B and $21M–$109M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jacky Abitbol participates in.

### When did Jacky Abitbol last invest?

The most recent investment recorded for Jacky Abitbol closed in May 2026. Shizune tracks 32 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co